Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial
Authors
Keywords
Antibodies, Booster doses, Vaccine development, SARS CoV 2, Vaccination and immunization, COVID 19, Enzyme-linked immunoassays, Recombinant vaccines
Journal
PLOS MEDICINE
Volume 19, Issue 5, Pages e1003953
Publisher
Public Library of Science (PLoS)
Online
2022-05-27
DOI
10.1371/journal.pmed.1003953
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
- (2022) Roos S.G. Sablerolles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Homologous and Heterologous Covid-19 Booster Vaccinations
- (2022) Robert L. Atmar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant
- (2022) Xin Zhao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients
- (2022) Corine H. GeurtsvanKessel et al. Science Immunology
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
- (2021) Merryn Voysey et al. LANCET
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
- (2021) Denis Y Logunov et al. LANCET
- Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
- (2021) Shilong Yang et al. LANCET INFECTIOUS DISEASES
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
- (2021) Marie Scully et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
- (2021) Andreas Greinacher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021
- (2021) Jessica R. MacNeil et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Considerations in boosting COVID-19 vaccine immune responses
- (2021) Philip R Krause et al. LANCET
- Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern
- (2021) Jingwen Ai et al. CELL RESEARCH
- Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
- (2021) Scott A Halperin et al. LANCET
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
- (2021) Alasdair P S Munro et al. LANCET
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
- (2021) Sara Y Tartof et al. LANCET
- Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
- (2021) Arabella S V Stuart et al. LANCET
- Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
- (2021) Shuo Feng et al. NATURE MEDICINE
- SARS-CoV-2 vaccine protection and deaths among US veterans during 2021
- (2021) Barbara A. Cohn et al. SCIENCE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started